Article Text

Download PDFPDF

1134 A novel mRNA therapeutic vaccine for polyomavirus associated merkel cell carcinoma
  1. Alexander Frey1,
  2. Curtis Perry1,
  3. Kathryn Clulo1,
  4. Kelly Olino2 and
  5. Jeffrey Ishizuka3
  1. 1Yale University, New Haven, CT, USA
  2. 2Yale New Haven Hospital, Department of Surgical Oncology, New Haven, CT, USA
  3. 3Yale University, Woodbridge, CT
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Merkel Cell Carcinoma (MCC) is a rare cutaneous neoplasm of neuroendocrine origin associated with integration of a truncated form of the Merkel Cell Polyomavirus Large T Antigen (LTA) in ~80% of U.S. cases.1 LTA is both antigenic and requisite for continued proliferation of MCC, making it an attractive target for a therapeutic vaccine strategy.2

Methods Expression of truncated LTA was induced in a B16-F10 melanoma cell line to create an in vivo murine MCC model. Modified mRNA coding for LTA was produced using in vitro transcription and was packaged in lipid nanoparticles for delivery by intramuscular injection. LTA expressing tumors were placed subcutaneously in C57BL/6 mice and treated with LTA vaccine or placebo with or without additional anti-PD1 antibody. Tumor growth and survival were measured and characterization of tumor immune infiltration by flow cytometry was performed. PBMCs and matched tumor cells from MCC patients were used to establish a model of in vitro vaccination. Monocyte derived dendritic cells (moDCs) were generated from the PBMC pool and were transfected with LTA mRNA. The PBMC pool was pulsed with antigen loaded or placebo moDCs every 7 days, and immunophenotypes, cytokine release, and specific tumor cell killing were assessed.

Results LTA mRNA treatment resulted in tumor growth suppression compared to placebo by day 21 (mean volume 199.8mm3 vs. 830.0mm3 P=.007 figure 1A) and increased median survival (35.5 vs. 25.5 days P=.004 figure 1A). Combination of vaccine with anti-PD1 outperformed monotherapy with growth suppression on day 21 (mean volume 103.2mm3 vs. 398.7mm3 P=.037 figure 1B). Treated murine tumors exhibited increased immune infiltration (mean CD45+ 11.56% vs. 7.81% P=.037 figure 1C). Among infiltrating lymphocytes, there was an increased proportion of CD3+ cells (mean 69.74% vs. 57.36% P=.0013 figure 1D), and CD8+ cells were more cytotoxic (MFI GZMB 26785 vs. 13607 P=.0026 figure 1E). In vitro vaccination of patient PBMCs resulted in expansion of CD8+ cells by day 35 (42.2% vs. 22.2% P=.0013 figure 2B), and an increase in activation and memory markers (PD1+ 13.9% vs. 3.91% P=.01; CD45RO+ 77.5% vs. 39.6% P=.009 figure 2C). Exposure of treated cells to antigen loaded DCs resulted in increased IFNg release (422.9pg/mL vs. 96.16pg/mL P<.0001 figure 2D) and increased specific tumor killing (Mean fluorescent count 12 vs. 9.5 P=.038 figure 2E).

Conclusions Treatment with a novel mRNA vaccine targeting LTA increases infiltration of cytotoxic immune populations, resulting in significant growth suppression and increased median survival. In vitro vaccination increases cytotoxic CD8+ populations, IFNg release, and specific killing of patient derived tumor cells.


  1. Paulson KG, Park SY, Vandeven NA, Lachance K, Thomas H, Chapuis AG, Harms KL, Thompson JA, Bhatia S, Stang A, Nghiem P. Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics. J Am Acad Dermatol. 2018 Mar;78(3):457–463.

  2. Houben R, Adam C, Baeurle A, Hesbacher S, Grimm J, Angermeyer S, Henzel K, Hauser S, Elling R, Bröcker EB, Gaubatz S, Becker JC, Schrama D. An intact retinoblastoma protein-binding site in Merkel cell polyomavirus large T antigen is required for promoting growth of Merkel cell carcinoma cells. Int J Cancer. 2012 Feb 15;130(4):847–56.

Ethics Approval Tumors were collected with the approval of the Yale University Institutional Review Board, IRB # 0609001869, approval date: 7/19/2022, and expiration Date: 7/18/2023. Participants gave informed consent before taking part. Animal studies were conducted with the approval of the Yale University Institutional Animal Care and Use Committee, protocol #2022–20307

Abstract 1134 Figure 1

(A) Treatment of mice bearing LTA expressing B16 tumors with LTA targeting vaccine resulted in significant growth suppression and increased survival compared to placebo and WT B16 tumors (n=10 per group). (B) Treatment of mice bearing LTA expressing B16 tumors with LTA targeting vaccine, aPD1, or combination suppressed tumor growth compared to placebo (n=10 per group). Ex-vivo flow cytometry of tumors revealed that LTA targeting vaccine treatment increased overall immune infiltration (C), T cell infiltration (D), and GZMB expression of infiltrating CD8+ T cells (E) with representative flow plots (n=10 per group). (*P≤0.05 **P≤0.01 ***P≤0.001 ****P≤0.0001)

Abstract 1134 Figure 2

(A) Schematic describing the process and timeline of in vitro vaccination. (B) Expansion of CD8+ and contraction of CD4+ populations in LTA treated PBMC pool over the course of 35 days (n=2 per group). (C) Frequency of activation and memory marker positivity in CD8+ and CD4+ populations for LTA and placebo treated PBMC pools (n=2 per group). (D) IFNg release by ELISA in response to co-culture with LTA loaded DCs or matched patient MCC tumor cells (n=4 per group left panel; n=6 per group right panel). (E) Measurement of specific tumor cell killing by europium release assay when co-cultured with LTA treated or placebo PBMC pool (n=2 per group). (*P≤0.05 **P≤0.01 ***P≤0.001 ****P≤0.0001)

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.